Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
NEW YORK, Feb. 19, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Anavex Life Sciences Corp. (NASDAQ:AVXL) securities between May 17, 2013 and December 28, 2015.
Click here to learn about the case: http://docs.wongesq.com/AVXL-Info-Request-Form-1048. There is no cost or obligation to you.
According to the complaint, Anavex issued misleading statements and failed to disclose that the Company had used a paid stock promoter to artificially inflate the Company’s share price.
On December 29, 2015, Anavex disclosed that it had received a subpoena from the SEC on December 22, 2015. Anavex stated, in part, that “[t]he Company believes the subpoena and investigation relate to the recent unusual activity in the market for the Company’s shares.” Then on December 30, 2015, Seeking Alpha published a report entitled “Anavex: A Regulatory Target Damaged By Incriminating Evidence.” On this news, Anavex stock fell $0.78, or 12.42%, to close at $5.50 per share.
If you suffered a loss in Anavex Life Sciences you have until February 29, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/AVXL-Info-Request-Form-1048.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
